ADCs: Manufacturing Practices, Challenges & the Road Ahead

ADCs: Manufacturing Practices, Challenges & the Road Ahead

ADCs are one of the fastest-growing areas of oncology innovation. Yet producing them remains a high-stakes, highly technical process – and new formats beyond the traditional ‘one antibody, one payload’ model are raising the bar even higher. Despite these pressures, 90% of ADC professionals report being “somewhat” to “extremely” satisfied with their current setups.

Developed by Hanson Wade Intelligence in collaboration with Cytiva, this report provides a timely, data-driven view of the current state and future of ADC production. Inside you’ll learn:

• Manufacturing practices – How developers and CDMOs manage production from preclinical through commercial scale, including the shift from in-house to outsourced models.
• Current pain points – Why challenges persist, with a focus on scale-up, technology transfer, analytical readiness and regulatory variability.
• Future outlook – Expectations for the next three to five years, including anticipated challenges and advances, with a focus on automation, AI/ML-driven process optimisation, linker and payload innovation, and improved analytical characterisation.